Biohaven_BHV1530-101 (Advanced or Metastatic Solid Tumors)

Purpose of this Study

We are doing this study to find the most effective, safe dose of an experimental drug called BHV-1530 (the study drug) for adults who have advanced or metastatic solid tumors.

Who Can Participate?

Eligibility

Adults ages 18+ who:
  • Have a solid tumor form of cancer
  • Have disease that is locally advanced/metastatic and has not responded to therapy or come back after therapy
For more information, contact the study team at hollie.watson@duke.edu.

Age Range

18-110

Sex/Genders

Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No

What is Involved?

Description

If you choose to join this study, you will:
  • Get the study drug as an intravenous (IV) infusion every 3 weeks
  • Have study visits between drug infusions that might include the following procedures: physical exams, echocardiograms, imaging scans (CT or MRI), eye exams, or tumor tissue sampling
You will get the study drug for as long as the study doctor believes that you are getting a benefit. The dose of the study drug that is given will vary depending on when you join the study.

Locations

Duke University Hospital

Visit Timing

Weekdays

Compensation

No

Spanish Materials Available

No

Study Details

Full Title

A Phase 1, Multicenter, Open-Label, Dose Escalation, Dose Expansion and Dose Confirmation Study of BHV-1530 in Adult Participants with Advanced or Metastatic Solid Tumors

Principal Investigator

Niharika
Mettu

Protocol Number

PRO00118213

NCT ID

NCT06874335

Phase

I

Enrollment Status

Pending Open to Enrollment
ClinicalTrials.gov